Miotolan is an oral anabolic derived from dihydrotestosterone. This agent is moderately anabolic, with only mild androgenic properties. This is no doubt due to the modification of the steroid’s A-ring, which allows the steroid structure to stay stable and bind receptors in muscle tissue long enough to provide an anabolic benefit. Furazabol was first developed in the 1960s. The only modern pharmaceutical preparation o f record containing furazabol, at least known to researches in the West, was miotolan from Daiichi Seiyaku Labs in Japan, which was sold in Japan mainly during the 1970’s and 80’s. The drug itself is scarcely mentioned in the Western medical literature, and consequently a great deal of myth has come to surround it around athletes. A realistic appraisal sits this drug in a very similar class to winstrol, however, with both agents being moderately strong anabolics with low androgenic activity. Aside from this, it is difficult to ascribe any drastically unique traits to this drug. Today, furazabol is very scarcely known to bodybuilders and athletes. The Miotolan brand from Japan was discontinued many years ago, and no pharmaceutical preparation containing furazabol has been known to exist since. The drug is still located on the black market, however, due to the fact that raw powder is still being produced in Asia. Currently, the actual number of products containing this drug is small, although it could easily expand if the market ever created a demand. It is unlikely that an actual prescription agent containing this substance will ever be seen again.